{"id":"NCT00620555","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","officialTitle":"A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2008-02-21","resultsPosted":"2011-12-20","lastUpdate":"2021-02-03"},"enrollment":65,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsies, Partial"],"interventions":[{"type":"DRUG","name":"gabapentin","otherNames":[]}],"arms":[{"label":"gabapentin","type":"EXPERIMENTAL"}],"summary":"Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)","timeFrame":"up to 53 weeks","effectByArm":[{"arm":"Gabapentin","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":22,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9451165&StudyName=A%20Phase%20III%20Open-Label%20Extension%20Study%20Of%20Gabapentin%20As%20Adjunctive%20Therapy%20In%20Japanese%20Pediatric%20Patients%20With%20Partial%20Seizures"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":65},"commonTop":["Nasopharyngitis","Somnolence","Influenza","Pyrexia","Diarrhoea"]}}